A Phase IV Study Of The Impact Of Vorinostat On Cellular Signaling And Cytokine Production In Cutaneous T-Cell Lymphoma Patients With Pruritus

Trial Profile

A Phase IV Study Of The Impact Of Vorinostat On Cellular Signaling And Cytokine Production In Cutaneous T-Cell Lymphoma Patients With Pruritus

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2015

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Mycosis fungoides
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Jan 2015 Planned End Date changed from 1 Mar 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 26 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 07 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top